Mifepristone (RU-486) in Androgen Independent Prostate Cancer
The purpose of this study is to determine the effects (good and bad) that mifepristone has on patients with androgen independent prostate cancer.
Prostate Cancer|Adenocarcinoma of Prostate
DRUG: Mifepristone
To determine the therapeutic efficacy of mifepristone in patients with androgen independent prostate cancer, 2 years
To determine the duration of response, time to disease progression and safety of mifepristone in patients with androgen independent prostate cancer
Patients will receive mifepristone, 200mg orally once a day. One treatment cycle is 28 days long. Patients will remain on treatment unless their cancer gets worse or they develop intolerable side effects.

At the end of each cycle a physical examination, routine blood tests, and hormone levels will be performed.

After every 3 cycles, one or more of the following will be performed: bone scan, chest x-ray, CT scan or MRI.